Hosted on MSN4mon
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination ...
Hosted on MSN11mon
MSD’s Keytruda sprints towards label expansion in endometrial cancer
Merck & Co has started the year off strong following a 12 January label expansion for Keytruda to treat certain types of advanced cervical cancer in combination with chemoradiotherapy. The ...
pharmaphorum5d
NICE approval for Keytruda a 'milestone' in lung cancer
Keytruda's label does not require treatment to be stopped after two years and the number of patients receiving treatment after two years remains small, NICE noted in its guidance. Longer term ...